- $4.24bn
- $2.49bn
- 48
- 44
- 38
- 39
Annual balance sheet for Vaxcyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 386 | 246 | 931 | 1,080 | 1,747 |
| Net Total Receivables | — | — | — | — | 20.3 |
| Prepaid Expenses | |||||
| Total Current Assets | 389 | 256 | 943 | 1,096 | 1,788 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.27 | 35.9 | 31.6 | 111 | 270 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 393 | 324 | 1,006 | 1,408 | 3,511 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 46.9 | 28.7 | 40.5 | 145 | 140 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 47 | 40.3 | 52.6 | 167 | 205 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 346 | 284 | 954 | 1,240 | 3,306 |
| Total Liabilities & Shareholders' Equity | 393 | 324 | 1,006 | 1,408 | 3,511 |
| Total Common Shares Outstanding |